X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
PHVS416 (deucrictibant) is a potent, selective, and orally available antagonist of the bradykinin B2 receptor, which is being evaluated for the treatment of hereditary angioedema attacks.
Lead Product(s): Deucrictibant
Therapeutic Area: Genetic Disease Product Name: PHVS416
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 18, 2024
Details:
PHVS416 (deucrictibant) is a potent, selective, and orally available antagonist of the bradykinin B2 receptor. It is being evaluated in phase 2/3 trials for the prophylactic treatment of HAE Attacks.
Lead Product(s): Deucrictibant
Therapeutic Area: Genetic Disease Product Name: PHVS416
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 22, 2024
Details:
PHVS416 (deucrictibant) is a bradykinin B2 receptor inhibitor small molecule drug candidate in oral soft gel capsule form for prophylaxis against hereditary angioedema.
Lead Product(s): Deucrictibant
Therapeutic Area: Genetic Disease Product Name: PHVS416
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2023
Details:
PHVS416 (deucrictibant) is an investigational softgel immediate-release capsule formulation containing PHA121, a highly potent, specific, and orally bioavailable competitive antagonist of the bradykinin B2 receptor, which is investigated for HAE attacks.
Lead Product(s): Deucrictibant
Therapeutic Area: Genetic Disease Product Name: PHVS416
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 26, 2023
Details:
Pharvaris will use the net proceeds to fund research and development of its drug candidates including, PHVS416 (deucrictibant), a highly potent, specific, and orally bioavailable competitive antagonist of the bradykinin B2 receptor, being developed for hereditary angioedema.
Lead Product(s): Deucrictibant
Therapeutic Area: Genetic Disease Product Name: PHVS416
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: General Atlantic
Deal Size: $70.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement June 20, 2023
Details:
PHVS416 is an investigational softgel capsule formulation containing PHA121, a highly potent, specific, and orally bioavailable competitive antagonist of the bradykinin B2 receptor.
Lead Product(s): PHA121
Therapeutic Area: Genetic Disease Product Name: PHVS416
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2022
Details:
Pharmacokinetic properties of PHA121 were evaluated to support the intended therapeutic use of PHVS719 for the prophylactic treatment of HAE attacks using preclinical and clinical experimental models.
Lead Product(s): PHA121
Therapeutic Area: Genetic Disease Product Name: PHVS416
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2022
Details:
PHVS416 is an investigational softgel capsule formulation containing PHA121, a highly potent, specific, and orally bioavailable competitive antagonist of the bradykinin B2 receptor.
Lead Product(s): PHA121
Therapeutic Area: Genetic Disease Product Name: PHVS416
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 07, 2022
Details:
The data demonstrate that PHA121 (aka PHVS416), is 25-fold more potent than icatibant at inhibiting bradykinin interaction with the endogenous human B2 receptor.PHA121 is a highly potent, specific, and orally bioavailable competitive antagonist of the bradykinin B2 receptor.
Lead Product(s): PHVS416
Therapeutic Area: Genetic Disease Product Name: PHA121
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 16, 2022
Details:
PHVS416/PHA121 (PHA-022121) is a highly potent, specific, and orally bioavailable competitive antagonist of the bradykinin B2 receptor that has completed Phase 1 clinical development for the treatment of HAE.
Lead Product(s): PHA121
Therapeutic Area: Genetic Disease Product Name: PHVS416
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 22, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
